Aarti Drugs Ltd Financials

Aarti Drugs Ltd Financial Statement

Aarti Drugs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	543.47	493.06	560.64
Operating Expense	483.55	438.73	490.47
Net Profit	30.39	26.91	36.14
Net Profit Margin	5.59	5.46	6.45
Earning Per Share	3.33	2.93	3.93
EBIDTA	57.92	53.83	71.67
Effective Tax Rate	14.19	14.26	21.52

Particulars	Sep 2024
Revenue	543.47
Operating Expense	483.55
Net Profit	30.39
Net Profit Margin	5.59
Earning Per Share	3.33
EBIDTA	57.92
Effective Tax Rate	14.19

Aarti Drugs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	2,266.91	2,497.97	2,251.17
Operating Expenses Annual	2,000.78	2,215.57	1,932.99
Operating Profit Annual	270.31	284.64	322.96
Interest Annual	30.16	32.53	20.07
Depreciation	45.50	44.64	44.28
Net Profit Annual	141.88	152.81	195.00
Tax Annual	50.60	52	60.50

Particulars	Mar 2024
Total Revenue Annual	2,266.91
Operating Expenses Annual	2,000.78
Operating Profit Annual	270.31
Interest Annual	30.16
Depreciation	45.50
Net Profit Annual	141.88
Tax Annual	50.60

Aarti Drugs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	1.52	1.49	2.84
Cash Flow from Operations	337.10	161.70	39.90
Cash Flow from Investing	-187.09	-131.14	-125.36
Cash Flow from Financing	-148.81	-30.54	84.11
Cash Flow at the End	2.72	1.52	1.49

Particulars	Mar 2024
Cash Flow at the Beginning	1.52
Cash Flow from Operations	337.10
Cash Flow from Investing	-187.09
Cash Flow from Financing	-148.81
Cash Flow at the End	2.72

Aarti Drugs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	12.06	11.54	14.48
PBIT Margin (%)	9.96	9.65	12.37
PBT Margin (%)	9.66	9.38	11.83
Net PROFIT Margin (%)	6.26	6.12	8.66
Return On Networth / Equity (%)	12.39	14.65	21.29
Return On Networth /Employed (%)	13.65	15.24	20.38
Return On Assets (%)	8.57	9.67	14.29
Total Debt / Equity (X)	0.44	0.51	0.47
Asset Turnover Ratio (%)	1.37	1.58	1.65

Particulars	Mar 2024
PBDIT Margin (%)	12.06
PBIT Margin (%)	9.96
PBT Margin (%)	9.66
Net PROFIT Margin (%)	6.26
Return On Networth / Equity (%)	12.39
Return On Networth /Employed (%)	13.65
Return On Assets (%)	8.57
Total Debt / Equity (X)	0.44
Asset Turnover Ratio (%)	1.37

Aarti Drugs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	722.29	634.48	649.41
Total Current Assets Annual	1,181.02	1,349.53	1,273.19
Non Current Assets Annual	990.60	845.96	761.33
Total Shareholders Funds Annual	1,175.21	1,114.30	972.17
Total Assets Annual	2,171.62	2,195.50	2,034.52

Particulars	Mar 2024
Fixed Assets Annual	722.29
Total Current Assets Annual	1,181.02
Non Current Assets Annual	990.60
Total Shareholders Funds Annual	1,175.21
Total Assets Annual	2,171.62

Aarti Drugs Ltd Earning Calls

EPS (INR)

Expected

3.84

Reported

3.83

Surprise

-0.26%

Jun 2024

EPS beaten by -0.26%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 22, 2024, Aarti Drugs Ltd has a market capitalization of 3,988.60 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Aarti Drugs Ltd is debt-free with a debt-to-equity ratio of 0.40.

In FY 2023 , Aarti Drugs Ltd recorded a total revenue of approximately 2,266.91 Cr marking a significant milestone in the company's financial performance.

Aarti Drugs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.0% annually, respectively..

Aarti Drugs Ltd's current PE ratio is 28.11.

Aarti Drugs Ltd's ROCE averaged 15.4% from the FY ending March 2022 to 2024, with a median of 14.4%. It peaked at 18.4% in March 2022, reflecting strong capital efficiency over the period..

Aarti Drugs Ltd's latest EBIT is Rs. 222.64 Cr, surpassing the average EBIT of Rs. 245.18 Cr over the 5 years..